SAN DIEGO, March 30 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that presentations by senior management and invited guest speakers at the company’s invitation-only Analyst and Investor Day will be webcast live beginning at noon Eastern Time on Thursday, April 6, 2006.
Mark R. Schleiss, M.D., American Legion Chair of Pediatrics, Associate Chair for Research, Department of Pediatrics, Professor, and Director of Pediatric Infectious Diseases and Immunology at the University of Minnesota, will present an overview on cytomegalovirus (CMV) disease. Andrew T. Pavia, M.D., George and Esther Gross Presidential Professor and Chief, Division of Pediatric Infectious Diseases at the University of Utah, will present an overview on influenza, including avian and potential pandemic strains. Vijay B. Samant, Vical’s President and Chief Executive Officer, will provide a brief overview on vaccine technologies. David C. Kaslow, M.D., Vical’s Chief Scientific Officer, will present summaries of the company’s CMV and avian influenza vaccine programs. The audio webcast and slides will be available through a link in the Webcast Center at www.vical.com. A replay will be available following completion of the live presentation.
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company has retained all rights to its internally developed product candidates. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and serve significant unmet medical needs. Additional information on Vical is available at www.vical.com.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company’s focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether the company’s vaccines for CMV or influenza, or any other product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company’s filings with the Securities and Exchange Commission. These forward-looking statements represent the company’s judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
Contacts: Investors: Media: Alan R. Engbring Susan Neath Vical Incorporated Porter Novelli Life Sciences (858) 646-1127 (858) 527-3486 Website: www.vical.com
Vical Incorporated
CONTACT: Investors, Alan R. Engbring of Vical Incorporated,+1-858-646-1127; or Media, Susan Neath of Porter Novelli Life Sciences,+1-858-527-3486, for Vical Incorporated
Web site: http://www.vical.com/
